doi:10.3969/j.issn.1004-583X.2016.01.029

Abstract

CLC Number:

R735

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.029

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/112

[1] 杨立学,马韬,张俊,等.伊立替康化学治疗的不良反应与UGT1A1* 28基因多态性的关系[J].内科理论与实践,2009,4(4):300-304.
[2] Douillard JY,Cunningham D,Roth AD,et al.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial[J].Lancet,2000,355(9209):1041-1047.
[3] Toffoli G,Cecchin E,Corona G,et al.Pharmacogenetics of irinotecan[J].Curr Med Chem Anticancer Agents,2003,3(3):225-237.
[4] Champoux JJ.DNA topoisomerases;structure,function,and mechanism[J]. Annu Rev Biochem,2001,70: 369-413.
[5] Ogawara D,Fukuda M,Nakamura Y,et al.Life-threatening toxicity in a patient with UGT1A1*6 heterozygous polymorphism after irinotecan-based chemotherapy:a case report[J].Acta Med Nagasaki,2014,59: 63-65.
[6] 曹凯,司继刚,孙敏,等.伊立替康相关腹泻及粒细胞缺乏致死亡[J].中国药物应用与监测,2014,11(1):57-59.
[7] 江伟,陈振东.FOLFIRI方案治疗老年结直肠癌安全性临床观察[J].安徽医科大学学报,2010,45(2):237-240.
[8] Alimonti A,Gelibter A,Pavese I,et al.New approaches to prevent intestinal toxicity of irinotecan-based regimens[J].Cancer Treat Rev,2004,30(6):555-561.
[9] 季楚舒,何义富,胡冰,等.UGT1A1*28 基因多态性与晚期结直肠癌伊立替康化疗疗效及不良反应的关系[J].肿瘤,2010,30(10):870-874.
[10] 王晖,武晓楠,丁丽,等.伊立替康相关不良反应与UGT1A1基因多态性的关系[J].现代肿瘤医学,2013,21(1):161-163.
[11] Dranitsaris G,Shah A,Spirovski B,et al.Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy:the development of a risk prediction tool[J].Clin Colorectal Cancer,2007,6(5):367-373.
[12] Duffour J,Gourgou S,Desseigne F,et al.Multicentre phase Ⅱ study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer[J].Cancer Chemother Pharmacol,2007,60(3):383-389.
[13] 张新玉,田辉.遗传性非结合型高胆红素血症[J].肝脏,2005,10(1):51-52.
[14] Takahara N,Nakai Y,Isayama H,et al.Uridine diphosphate glucuronosyl transferase1 family polypeptide A1gene(UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer[J].Cancer Chemother Pharmacol,2013,71(1):85-92.
[15] Desai AA,Innocenti F,Ratain MJ.UGT pharmacogenomics:implications for cancer risk and cancer therapeutics[J].Pharmacogenetics,2003,13(8):517-523.
[16] Hirose K,Kozu C,Yamashita K,et al.Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene[J].Oncol Lett,2012,3(3):694-698.
[17] Liu CY,Chen PM,Chiou TJ,et al.UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma[J].Cancer,2008,112(9):1932-1940.
[18] Sanoff HK,Sargent DJ,Green EM,et al.Racial differences in advanced colorectal cancer outcomes and pharmacogenetics:a subgroup analysis of a large randomized clinical trial[J].J Clin Oncol,2009,27(25):4109-4115.
[19] Teh LK,Hashim H,Zakaria ZA,et al.Polymorphisms of UGT1A1*6,UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia[J].Indian J Med Res,2012,136(2):249-259.
[20] Innocenti F,Undevia SD,Iyer L,et al.Genetic variants in the UDP-glucuronosyl transferase 1A1 gene predict the risk of severe neutropenia of irinotecan[J].J Clin Oncol,2004,22(8):1382-1388.
[21] Wang Y,Shen L,Xu N,et al.UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil[J].World J Gastroenterol,2012,18(45):6635-6644.
[22] Martinez-Balibrea E,Abad A,Martínez-Cardús A,et al.UGT1A1 and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy[J].Br J Cancer,2010,103(4):581-589.
[23] Okuyama Y,Hazama S,Nozawa H,et al.Prospective phase Ⅱ study of FOLFIRI for mCRC in Japan,including the analysis of UGT1A1*28/*6 polymorphisms[J].Jpn J Clin Oncol,2011,41(4):477-482.
[24] Hu ZY,Yu Q,Zhao YS,et al.Dose-dependent association between UGT1A1 *28 polymorphism and irinotecan-induced diarrhea:a meta-analysis[J].Eur J Cancer,2010,46(10):1856-1865.
[25] Schulz C,Heinemann V,Schalhorn A,et al.UGT1A1 gene polymorphism:impact on toxicity and efficacy of irinotecan-based regiments in metastatic colorectal cancer[J].World J Gastroenterol,2009,15(40):5058-5066.
[26] Braun MS,Richman SD,Thompson L,et al.Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer:the FOCUS trial[J]. J Clin Oncol,2009,27(33):5519-5528.
[27] 李虎,黄鹤,刘继红.UT1A1基因启动子多态性与伊立替康化疗毒性作用的关系[J].中华妇产科杂志,2011,46(12):888-891.
[28] Sunakawa Y,Ichikawa W,Fujita K,et al.UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer[J].Cancer Chemother Pharmacol,2011,68(2):279-284.
[29] Fujita K,Sasaki Y.Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy[J].Curr Drug Metab,2007,8(6):554-562.
[30] Minami H,Sai K,Saeki M,et al.Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:roles of UGT1A1*6 and *28[J].Pharmacogenet Genomics,2007,17(7):497-504.
[31] Yamashita K,Nagashima F,Fujita K,et al.Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer[J].Jpn J Clin Oncol,2011,41(2):204-209.
[32] Satoh T,Ura T,Yamada Y,et al.Genotype-directed,dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms[J].Cancer Sci,2011,102(10):1868-1873.
[33] 徐建明.伊立替康联合氟尿嘧啶治疗晚期结直肠癌的疗效和毒性的预测研究[D].军事医学科学院附属医院,2009.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhao Xuhui, Huang Xiaomin, Da Dezhuan, Xu Yan, Cui Xiaodong, Li Hongling. Screening of glycolysis-related genes for predicting the prognosis of patients with gastric cancer: Based on bioinformatics [J]. Clinical Focus, 2024, 39(1): 20-29.
[2]	Zhu Chenglou, Wu Qiong, Da Mingxu. Risk assessment of pancreatic cancer in patients with type 2 diabetes mellitus treated with sitagliptin: A meta-analysis of randomized controlled trials [J]. Clinical Focus, 2023, 38(12): 1061-1066.
[3]	Wang Junhong, Gao Zhenhua, Zhang Ronglong, Ji Haomin, Zhao Xinke, Da Mingxu. Quality analysis of the literatures associated with gastric cancer diagnosis from 1980-2021——A bibliometric analysis based on the Web of Science database [J]. Clinical Focus, 2023, 38(12): 1117-1124.
[4]	. [J]. Clinical Focus, 2023, 38(11): 1048-1052.
[5]	Lyu Chang, Zhou Liming. Correlation between the TNF-α-308 gene polymorphism and gastric cancer susceptibility: A meta-analysis [J]. Clinical Focus, 2023, 38(9): 779-787.
[6]	You Yi, Gao Shuqing, Xu Hao. Effect of enteral nutrition on postoperative clinical outcome of esophageal neoplasms: A meta-analysis [J]. Clinical Focus, 2023, 38(6): 485-492.
[7]	Li Ya, Du Taoming, Qiu Shixiang, Chen Chao, Zhong Liming. Study on brain functional connectivity in patients with liver cancer with depression [J]. Clinical Focus, 2023, 38(6): 532-536.
[8]	Wang Yingnan, Zhao Qi, Bai Haiwei, Wu Danna, Wei Jinmei, Li Shengjiang, Li Ruiling, Zhang Ruixing. Clinical characteristics and risk factors of gastric cancer-related stroke [J]. Clinical Focus, 2023, 38(5): 417-422.
[9]	. [J]. Clinical Focus, 2023, 38(5): 473-476.
[10]	Shi Yujuan, Wang Jing, Xu Ping. Comparative analysis on pathological results of preoperative & postoperative colorectal intraepithelial neoplasia and early colorectal cancer endoscopic therapies [J]. Clinical Focus, 2023, 38(1): 55-59.
[11]	Zhang Yiming, Li Mingzhao, Gu Xin. Clinicopathological analysis of colorectal mixed adeno-neuroendocrine carcinoma: 8 cases report [J]. Clinical Focus, 2022, 37(10): 921-926.
[12]	Wang Chengyao, Zhang Zheng, Wu Jing. Meta analysis on correlation between sporadic duodenal neoplasm and colorectal neoplasm [J]. Clinical Focus, 2022, 37(7): 581-590.
[13]	Li Ya, Qiu Shixiang, Chen Chao, Zhong Liming. Depression-related factors and corresponding correlations with quality of life in patients with hepatocellular carcinoma [J]. Clinical Focus, 2022, 37(6): 539-543.
[14]	Tao Jianan, Tian Wangzhao, An Qi, Wang Xuehong, Zhang Shengqi, Liu Ji. Expression and clinical significance of SLP-2 in gastric cancer: A meta-analysis [J]. Clinical Focus, 2022, 37(4): 299-304.
[15]	Zhang Limin, Sun Jun. Predictive value of FIB-4 in patients with metabolic-associated fatty liver disease complicated with colorectal adenomatous polyps [J]. Clinical Focus, 2022, 37(4): 334-338.